logo
The healthcare sector is unloved – this trust is a prime example

The healthcare sector is unloved – this trust is a prime example

Telegraph4 days ago
Questor is The Telegraph's stock-picking column, helping you decode the markets and offering insights on where to invest.
Questor believes the healthcare sector is looking unloved at the moment. Sven Borho, the co-manager of Worldwide Healthcare Trust, the largest investment trust focused on the sector, agrees. In fact, he thinks the sector has been out of favour for most of the past decade.
Borho puts the blame for this squarely on the US debate around drug pricing, and while Questor agrees that it has had a big impact on sentiment, so too has the shift from the low inflation/low interest rate environment that prevailed before 2022.
While there had been mutterings about drug prices for a long time, it was a tweet by Hillary Clinton in September 2015, who was then on the campaign trail, that sparked an upset in the sector. She was promising to tackle price-gouging in the speciality drug market, which set the ball rolling on a series of measures from both sides of the US political divide.
Recently, this has culminated in President Trump's May 2025 executive order aimed at bringing US prices for patented drugs down to the levels charged in other countries. Last week's threat of a 200pc tariff on imports of drugs manufactured outside the US is another complicating factor.
However, Borho feels that investors have tended to be overly negative in response to threats to control drug prices. He also observes that, historically, Republican presidents have been good for the sector.
The Trump administration's choices for the heads of the various Federal healthcare bodies may have been controversial, but Borho's sense is that bodies such as the Food and Drug Administration (FDA) are becoming more efficient.
In recent years, the trust's high exposure to biotech companies has weighed on its performance. As outlined in this column's recent appraisal of RTW Biotech Opportunities, the biotech sector suffers not only from political pressures but a low sentiment from an investor base currently wary of loss-making and unproven companies – unfortunately, the bread and butter of the biotech industry.
Nevertheless, Borho is keen to stick with this approach as he believes that, over the long run, capturing the benefits of innovation is key to generating outsized returns.
He points out that biotech companies were responsible for almost two thirds of all clinical trials that began last year and most – 85pc – of the novel products approved.
At the same time, many big pharmaceutical companies face the prospect of lucrative products coming off patent and these companies need to acquire promising biotech businesses to maintain their revenue lines.
Relative to its benchmark, Worldwide Healthcare is underweight big pharma, which was 40pc of the MSCI index at the end of June but 18pc of the trust's portfolio – it had a corresponding overweight exposure to biotech.
However, there are also exciting developments in areas beyond biotech. Over Worldwide Healthcare's latest financial year, some of the strongest contributors to its returns were medical equipment companies, including Boston Scientific and Intuitive Surgical.
Boston Scientific has been making great strides in the cardiovascular field, while Intuitive Surgical's da Vinci robotic surgery equipment is delivering better surgical outcomes for patients.
Medical technology and devices accounted for a third of the trust's portfolio at the end of June.
Worldwide Healthcare turned 30 in April, and was one the best-performing trusts over that period, offering a total return of about 4,000pc. However, over the past five years, the trust has lost money for shareholders.
Unsurprisingly, that has put pressure on its share price discount to net asset value. The board says that it will buy back stock when the discount is wider than 6pc, but for most of the past 12 months the discount has been in double digits, which opened the door to activist Saba to build a 5pc stake in the trust.
The board has stepped up the pace of share buybacks and both the discount and Saba's stake appear to be coming down now.
Questor agrees with the manager that there is plenty to get excited about in the healthcare sector over the next few years. Borho foresees a time when most cancer is treated as a chronic disease and much is curable.
He predicts advances in the area of neurodegenerative disease such as Alzheimer's and Parkinson's to help improve and extend lives and hopes new gene therapies will cure rare diseases. He also thinks that artificial intelligence will help guide diagnoses, relieving pressure on GPs.
Other trusts with a similar remit have done a better job of navigating this difficult period for the sector, so the big question is whether Worldwide Healthcare is the best way to take advantage of this theme.
While the jury is out, the successful history of the trust can't be ignored.
Questor says: hold
Ticker: WWH
Share price: £3.07
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

EXCLUSIVE The truth about 'suicide headaches' and the bizarre treatments I tried in search of a cure
EXCLUSIVE The truth about 'suicide headaches' and the bizarre treatments I tried in search of a cure

Daily Mail​

time10 minutes ago

  • Daily Mail​

EXCLUSIVE The truth about 'suicide headaches' and the bizarre treatments I tried in search of a cure

Tom Zeller Jr has done just about anything to get rid of his headaches. He's chugged 60 glasses of water in a day, inhaled oxygen straight from the tank and even tripped on magic mushrooms on top of the western Montana mountains. The 56–year–old science journalist was diagnosed about three decades ago with cluster headaches, debilitating headaches that strike randomly and drag out for weeks or months at a time. While it could be years between attacks, they return as fast as a lightning strike, with Zeller likening them to resting your hand on a hot burner and not being able to take it off. Zeller told 'They're excruciatingly painful. The tend to come on really, really quickly, within a matter of seconds. You don't usually have a warning and they will knock you down to the floor until they're over.' Zeller, who lives in Montana, spent much of his adult life suffering attacks up to four times a day for months at a time until they suddenly disappeared. His clusters have slowed in recent years, but like the 1 in 1,000 Americans with the disorder, Zeller waits for the next attack with limited tools at his disposal. In his newly released book, The Headache: The Science of a Most Confounding Affliction – and a Search for Relief, Zeller detailed his decades–long search for cluster headache relief, along with the wackiest things he's tried to quell the pain. 'I never wanted to write this book, to be honest. I did not want people to know I had headaches. It's just terrible to be seen in this way,' Zeller told 'But I also felt like if you're going to write a book, they say, "Write about what you know." I realized that I know headaches.' Cluster headaches are extremely painful and strike quickly in frequent attacks, or 'clusters,' lasting weeks or months at a time, earning the grim nickname 'suicide headaches.' The disorder usually causes sharp and stabbing pain in or around the eye, restlessness, tears and eye redness, forehead sweating, swelling around the eye and eyelid drooping. While a close relative of migraines, they're far less common. About 0.1 percent of Americans have had a cluster headache attack at some point in their lives, while 15 percent – most of whom are women – have migraines. For Zeller, the attacks drove a wedge in his journalism career, often forcing him to 'retreat from opportunities in the newsroom.' 'It's not easy. The book talks about how any sort of headache disorder is kind of a drag on the momentum of your life. They're always slowing you down,' he said. 'When I wasn't having the headaches, I felt like I was pretty bold and pretty accomplished as a journalist. But when the headaches would come on, I would sort of disappear and I would work from home a lot. 'There's a lot of stigma attached to headaches in a weird way. I tried very hard to make sure that no one knew that I had these headaches. You start to hide and that meant hiding from opportunities at work too.' Throughout the book, Zeller detailed a laundry list of unorthodox treatments he tried or researched. 'I was being ground down by the relentless injections, self–administered into an abdomen bruised and pockmarked by previous jabs, and overuse of the medication was likely driving an endless cycle of rebound attacks,' he wrote in his book. 'Given this unappealing tableau, why not shrooms?' Psilocybin, the active compound in magic mushrooms, has been shown to alter how the brain processes and perceives pain signals and is thought to reduce inflammation. He's also tried inhaling capsaicin, an extract in chili peppers that gives them their signature heat. Some research suggests it helps desensitize nerve fibers in the nasal passages that transmit cluster headache pain to the brain. Zeller also rented oxygen tanks from a welding supplier as a 'really fast way to abort a cluster headache attack.' 'I also remember a forum saying that if you just tried to chug like 60 glasses of water a day, or some absurd amount, it would cure your headaches. I was willing to try, but all I did was visit the toilet a lot with headaches,' he recalled. Zeller said many patients with cluster headaches have to rely on bizarre hacks because of the lack of medications geared specifically toward their condition. 'The thing that surprised me most, and what probably prompted the book, was that so little research was out there on primary headache disorders,' Zeller explained. Patients are often prescribed beta blockers, antipsychotics, antidepressants and other drugs manufactured for other illnesses, as they can treat headaches in some people. Recently, the advent of CGRP drugs has changed the picture. Approved by the FDA in 2018, these preventative drugs block or reduce the effects of CGRP, which causes migraine and cluster headache pain. 'A lot of times you'll find a drug or remedy that does kind of work, but the body adapts. We're very plastic, and over time, those things start to wane,' Zeller said. Zeller uses the CGRP medication Emgality, the only FDA approved medication specifically designed for cluster headaches and migraines. The cluster headache dose of Emgality is significantly higher than the migraine dose – 300 milligrams compared to 120 milligrams – and both versions are given through a subcutaneous injection just under the skin. 'Cluster headaches are their own unique animal, so once the headaches start happening, it does seem to be pretty hard to stop,' Zeller revealed. 'But I think three times in I'm sort of convinced that the CGRP blockers work for me to stop a bout from happening.' Like migraines, cluster headaches often become less frequent and severe with age, which some research suggests could be due to hormonal fluctuations and altered blood vessel function in the brain. Zeller's clusters in recent years have slowed and can now fall years apart, but he's far from being in remission. 'I don't think I, or anyone really, is out of the woods yet,' he said. For now, Zeller said he hopes his new book will help improve cluster headache awareness and provide a sense of community for readers with the condition. In his research, he spoke with several cluster headache and migraine patients who at first were 'guarded' and wary of speaking about their experience over fears of it being trivialized. But throughout the interviews, they became excited because they had 'this pent–up desire to just unload about it.' 'I hope they feel seen by the book,' Zeller said. 'Someone out there is paying attention and you can take heart in that, and if you're able to buy time between painful bouts, I hope that you know the book will be affirming in that you know you're not alone.' The Headache: The Science of a Most Confounding Affliction – and a Search for Relief is available on Amazon, Barnes & Noble, Target and others.

I ran the lives of the Obamas for two years
I ran the lives of the Obamas for two years

Times

time16 minutes ago

  • Times

I ran the lives of the Obamas for two years

T he moment Donald Trump arrived to take occupancy of the White House was, of course, marked as he meant to go on by a bit of protocol-defying trouble. One hand — unseen behind the front door — was there to fix it. For days the White House had rehearsed the mechanics of how Donald and Melania Trump would ascend the North Portico steps to greet Barack and Michelle Obama, the outgoing president and first lady of the United States. No gifts, then handshakes, then photographs. Deesha Dyer was in her last hours as the White House social secretary for the Obamas in January 2017, hiding herself in a fold of curtain at the front window to supervise this crucial encounter. As soon as she spied Melania appearing out of the car with an enormous turquoise Tiffany & Co box, 'I was so mad … so mad,' Dyer writes in her new memoir, Undiplomatic. 'I'd confirmed with the Trump advance team there would be no gift exchange.'

My partner saved my life with a kiss – he spotted sign of silent killer after our smooch
My partner saved my life with a kiss – he spotted sign of silent killer after our smooch

The Sun

time40 minutes ago

  • The Sun

My partner saved my life with a kiss – he spotted sign of silent killer after our smooch

A MUM said she was saved from dying from suspected sepsis during childbirth by her partner spotting something was wrong as he kissed her. Kerri-Louise Gilchrist, 33, said Hugh Marshall, 35, noticed she was cold and her lips were blue. 3 3 3 The mum of two said he told medics at Worcester Hospital: 'That's a sign of sepsis.' Kerri was put on an IV drip before the birth of Layla last August. She later lost five pints of blood and required two transfusions. Kerri, from Great Malvern, Worcs, said: 'The nurses didn't notice anything until my partner said to them, you're not actually looking at your patient, her palms and lips are blue - that's a sign of sepsis. 'I'd been like that for a couple of hours at that point. 'Within two minutes of him saying that, I had 11 people in the room. 'You have somebody that's going to stand your ground for you. 'I was in no fit state to argue for myself, I couldn't care for myself. 'I wouldn't be here if it wasn't for Hugh.' Worcestershire Acute Hospitals NHS Trust said: 'We are sorry if Kerri is unhappy with the care she received.' The signs and symptoms of sepsis to look out for, according to The UK Sepsis Trust What are the symptoms of sepsis? SEPSIS is a life-threatening reaction to an infection that happens when your immune system overreacts and starts to damage your body's own tissues and organs. Symptoms of sepsis in an adult include: Acting confused, slurred speech or not making sense Blue, grey, pale or blotchy skin, lips or tongue – on brown or black skin, this may be easier to see on the palms of the hands or soles of the feet A rash that does not fade when you roll a glass over it, the same as meningitis Difficulty breathing, breathlessness or breathing very fast Symptoms in a child include: Blue, grey, pale or blotchy skin, lips or tongue – on brown or black skin, this may be easier to see on the palms of the hands or soles of the feet A rash that does not fade when you roll a glass over it, the same as meningitis Difficulty breathing (you may notice grunting noises or their stomach sucking under their ribcage), breathlessness or breathing very fast A weak, high-pitched cry that's not like their normal cry Not responding like they normally do, or not interested in feeding or normal activities Being sleepier than normal or having difficulty waking They may not have all these symptoms. If you think you or someone else has symptoms of sepsis, call 999 or go to A&E. Source: NHS

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store